Mar E. H.
- Country
- Spain
- Department
- Pediatric Nephrology
Research Overview
- A Phase 3, Open-label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Treatment of Anemia in Pediatric Participants with Chronic Kidney Disease
- Evaluation of Sparsentan in Pediatric Patients with Proteinuric Glomerular Diseases: A Phase 2, Open-Label, Single-Arm Cohort Study
- Evaluation of Safety and Efficacy of Sodium Zirconium Cyclosilicate in Pediatric Hyperkalemia: An Open-Label Study
Data & Insights
Has run more than one trial at 80 of 111 partner sites.
Specializations
Rare Blood Disorders
The investigator specializes in treating rare hematological conditions, with particular focus on Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) in pediatric populations.
- Complement-mediated disorders
- Pediatric hematology
- Blood disorder therapeutics
The investigator's work involves innovative complement inhibitor therapies for rare blood conditions.
Renal Medicine
Dedicated to advancing treatments for pediatric kidney conditions, particularly chronic kidney disease and associated complications including proteinuria and hyperkalaemia.
- Pediatric nephrology
- Renal protection strategies
- Electrolyte management
The investigator explores novel therapeutic approaches for managing kidney disorders in children and young adults.
Pediatric Therapeutic Development
Focuses on developing treatments for complex pediatric conditions, including childhood idiopathic nephrotic syndrome and anemia associated with chronic kidney disease.
- Pediatric drug development
- Long-term safety studies
- Treatment optimization
The investigator evaluates innovative therapeutic approaches for pediatric patients with chronic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.